Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$8.03 +1.6%	$8.72	$56.35 ▼ $105.00	$232.75M	0.95	12,438 shs	73,960 shs
MBX MBX Biosciences	$14.31 -6.9%	$12.68	$4.81 ▼ $27.50	$480.73M	N/A	326,858 shs	242,399 shs
NLTX Neoleukin Therapeutics	$19.98 -0.1%	$20.32	$2.03 ▼ $14.36	$187.77M	1.11	50,104 shs	82,355 shs
SBPH Spring Bank Pharmaceuticals		$8.00	$0.80 ▼ $4.80	$122.94M	1.07	177,606 shs	N/A

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	-4.01%	+5.33%	-4.59%	+7.19%	-88.42%
MBX MBX Biosciences	+10.66%	+15.39%	+5.49%	+22.76%	+1,536,999,900.00%
NLTX Neoleukin Therapeutics	-0.05%	-2.30%	-12.06%	+16.91%	-45.63%
SBPH Spring Bank Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MBX MBX Biosciences	2.3814 of 5 stars	3.5	0.0	0.0	0.0	2.6	1.7	0.6
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SBPH Spring Bank Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTE Aerovate Therapeutics	0.00	N/A	N/A	N/A
MBX MBX Biosciences	3.00	Buy	$37.63	162.93% Upside
NLTX Neoleukin Therapeutics	0.00	N/A	N/A	N/A
SBPH Spring Bank Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SBPH, MBX, AVTE, and NLTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/5/2025	MBX MBX Biosciences	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
7/16/2025	MBX MBX Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00

(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A	N/A
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	$11.08 per share	N/A
SBPH Spring Bank Pharmaceuticals	N/A	N/A	N/A	N/A	$2.16 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTE Aerovate Therapeutics	-$75.52M	-$1.70	N/A	N/A	N/A	N/A	-90.19%	-77.47%	11/10/2025 (Estimated)
MBX MBX Biosciences	N/A	-$4.54	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NLTX Neoleukin Therapeutics	-$57.56M	-$3.11	N/A	∞	N/A	N/A	-37.22%	-30.91%	N/A
SBPH Spring Bank Pharmaceuticals	-$24.10M	-$1.47	N/A	N/A	N/A	N/A	-89.89%	-52.89%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	N/A
SBPH Spring Bank Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTE Aerovate Therapeutics	N/A	8.78	8.78
MBX MBX Biosciences	N/A	N/A	N/A
NLTX Neoleukin Therapeutics	N/A	15.33	15.33
SBPH Spring Bank Pharmaceuticals	N/A	5.11	5.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTE Aerovate Therapeutics	N/A
MBX MBX Biosciences	N/A
NLTX Neoleukin Therapeutics	52.37%
SBPH Spring Bank Pharmaceuticals	17.17%

Insider Ownership

Company	Insider Ownership
AVTE Aerovate Therapeutics	24.90%
MBX MBX Biosciences	52.19%
NLTX Neoleukin Therapeutics	1.58%
SBPH Spring Bank Pharmaceuticals	12.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTE Aerovate Therapeutics	20	28.99 million	21.69 million	Optionable
MBX MBX Biosciences	36	33.59 million	N/A	N/A
NLTX Neoleukin Therapeutics	90	9.40 million	9.25 million	No Data
SBPH Spring Bank Pharmaceuticals	30	17.27 million	N/A	Not Optionable

SBPH, MBX, AVTE, and NLTX Headlines

Recent News About These Companies

Capital One Bank Review

October 18, 2024 | marketwatch.com

Punjab National Bank IFSC Code, MICR Code for location Jhunjhunu Opp B D Khaitan Hospital Rajasthan

October 6, 2024 | india.comI

Discover Bank Review (August 2024)

August 8, 2024 | marketwatch.com

Primark late May bank holiday 2024 opening times: What time are stores open on Monday 27?

May 23, 2024 | thesun.co.uk

Co-op early May bank holiday 2024 opening times: What time are stores open?

May 23, 2024 | thesun.co.uk

How many bank holidays are in May? How to get the most from your holiday allowance

May 10, 2024 | uk.finance.yahoo.com

Supermarket May bank holiday opening times 2024 including Tesco, Aldi, Morrisons and more

May 6, 2024 | mirror.co.ukM

May Bank Holidays 2023

May 6, 2024 | birminghammail.co.ukB

When will interest rates go down?

January 31, 2024 | thetimes.co.ukT

Bank of Canada expected to 'cautiously' start cutting rates in spring: Deloitte Canada

January 6, 2024 | ca.finance.yahoo.com

Man stabbed during street fight in Spring Bank West

September 29, 2023 | hulldailymail.co.uk

When is the next Bank Holiday and how many are left in 2023?

August 13, 2023 | dailyecho.co.ukD

Spring Bank fight involved two feuding families, police believe

August 8, 2023 | hulldailymail.co.uk

Calls for more police patrols on Spring Bank after fight leaves three in hospital

August 8, 2023 | hulldailymail.co.uk

Spring Bank fight: Six men and a woman held over shocking street violence

August 7, 2023 | hulldailymail.co.uk

The mysterious structure on Spring Bank created to shoot out a beam of light

August 5, 2023 | hulldailymail.co.uk

Syria’s Economic Outlook- Spring 2016

July 23, 2023 | worldbank.orgW

Holiday spending by bank’s customers jumped by 40% annually this spring

July 17, 2023 | independent.co.ukI

Hull's Spring Bank set for major regeneration as plans announced to make it more 'attractive'

June 30, 2023 | hulldailymail.co.uk

Spring 2023 Layoff Tracker: Grubhub Cuts 400 Staff

June 14, 2023 | forbes.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBPH, MBX, AVTE, and NLTX Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

$8.03 +0.13 (+1.65%)

As of 08/26/2025

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

MBX Biosciences NYSE:MBX

$14.31 -1.06 (-6.90%)

Closing price 04:00 PM Eastern

Extended Trading

$14.77 +0.46 (+3.21%)

As of 05:43 PM Eastern

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Neoleukin Therapeutics NASDAQ:NLTX

$19.98 -0.01 (-0.05%)

As of 08/25/2025

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Spring Bank Pharmaceuticals NASDAQ:SBPH

Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of a range of cancers and inflammatory diseases using its proprietary small molecule nucleotide platform. The company is developing SB 11285, a next-generation immunotherapeutic cyclic dinucleotide for the treatment of selected cancers; novel STING antagonist compounds for the treatment of autoimmune and inflammatory diseases; and novel platform to enable the targeted delivery of payload molecules. It has a collaboration agreement with with Roche to explore the co-administration of SB 11285. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time